Event to begin at 8:00 AM ET WOBURN, Mass. , March 21, 2022 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and